| scholarly article | Q13442814 |
| P50 | author | Harel Dahari | Q92027788 |
| Alan S. Perelson | Q55719625 | ||
| P2093 | author name string | Thomas J Layden | |
| Jennifer E Layden-Almer | |||
| P2860 | cites work | Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study | Q24797971 |
| Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo | Q27473043 | ||
| Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection | Q27481003 | ||
| Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin | Q27481147 | ||
| Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy | Q27485474 | ||
| Efficient initiation of HCV RNA replication in cell culture | Q27860520 | ||
| Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy | Q27860724 | ||
| Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients | Q33675362 | ||
| National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. | Q34156940 | ||
| HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). | Q40166878 | ||
| Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy | Q42725944 | ||
| Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss | Q42909353 | ||
| Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection | Q42978693 | ||
| Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. | Q42981018 | ||
| Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection | Q42981326 | ||
| Antiviral action of ribavirin in chronic hepatitis C. | Q42983488 | ||
| Modelling how ribavirin improves interferon response rates in hepatitis C virus infection | Q42989468 | ||
| Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. | Q42991291 | ||
| Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production | Q42991802 | ||
| Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors | Q42996917 | ||
| Kinetics of hepatitis C virus reinfection after liver transplantation | Q42997969 | ||
| Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus | Q42999229 | ||
| Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders | Q43000568 | ||
| Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a | Q43031033 | ||
| Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. | Q43033959 | ||
| Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection | Q43035013 | ||
| Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study | Q43035085 | ||
| Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo | Q43036832 | ||
| Hepatitis C virus kinetics during and immediately after liver transplantation. | Q43036834 | ||
| Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir | Q43037585 | ||
| Triphasic decline of hepatitis C virus RNA during antiviral therapy | Q43038759 | ||
| Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients | Q43039768 | ||
| First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline | Q43039947 | ||
| Hepatitis C virus kinetics in chimeric mice during antiviral therapy | Q43041357 | ||
| First phase hepatitis c viral kinetics in previous nonresponders patients | Q43042198 | ||
| Dynamics of alanine aminotransferase during hepatitis C virus treatment | Q43047530 | ||
| Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon | Q43048289 | ||
| Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin | Q43048292 | ||
| Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. | Q43708586 | ||
| Mathematical Analysis of Antiretroviral Therapy Aimed at HIV-1 Eradication or Maintenance of Low Viral Loads | Q44731505 | ||
| Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b | Q45722132 | ||
| Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa | Q45761962 | ||
| HIV-1 infection and low steady state viral loads | Q48646269 | ||
| Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. | Q50574695 | ||
| P433 | issue | 3 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 97-105 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Current hepatitis reports | Q26853829 |
| P1476 | title | Hepatitis C Viral Kinetics in Special Populations | |
| P478 | volume | 7 |
| Q34759489 | A perspective on modelling hepatitis C virus infection |
| Q34279897 | Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami |
| Q50554938 | Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients |
| Q35008521 | HCV RNA decline in the first 24h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin |
| Q35610571 | Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. |
| Q37130266 | Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene |
| Q27488804 | Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon |
| Q26824804 | Quantification of viral infection dynamics in animal experiments |
| Q34788754 | Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients |
Search more.